Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes' C) colon cancer

Colon cancer (adjuvant) - capecitabine and oxaliplatin: review decision - June 2011 information

Appendix A: decision paper presented to the Institute's Guidance Executive (PDF 59 KB)

Review Proposal - April 2011 information

Appendix A: provisional matrix of stakeholders (PDF 63 KB)

Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 445 KB)

Review Decision - October 2009 information

Appendix A: decision paper considered by the Institute's Guidance Executive (PDF 94 KB)

Review Proposal - August 2009 information

Appendix A: provisional matrix of stakeholders (PDF 35 KB)

Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 128 KB)

Colon cancer (adjuvant) - capecitabine & oxaliplatin (final appraisal determination) information

Colon cancer (adjuvant) - capecitabine & oxaliplatin (final appraisal determination) (PDF 130 KB)

Consultee and commentator comments on Appraisal Consultation Document (PDF 100 KB)

Appraisal Consultation Document: Colon cancer (adjuvant) - capecitabine & oxaliplatin  information

Overview (PDF 201 KB)

Colon cancer (adjuvant) - capecitabine and oxaliplatin: assessment report (PDF 2.11 MB)

Response to Consultee Comments (PDF 43 KB)

Consultee and commentator comment on the assessment report

Colon Cancer Concern (PDF 14 KB)

Institute for Cancer Research (PDF 14 KB)

NHS QIS (PDF 27 KB)

Royal College of Nursing (PDF 25 KB)

Royal College of Physicians (PDF 50 KB)

Non-manufacturer submissions

British Oncology Pharmacy Association (1) (PDF 45 KB)

British Oncology Pharmacy Association (2) (PDF 47 KB)

CancerBACUP (PDF 50 KB)

Cancer Concern (PDF 39 KB)

Joint submission - Royal College of Physicians, the Royal College of Radiologists, the Association of Cancer Physicians and the Joint Collegiate Council for Oncology (PDF 28 KB)

Royal College of Nursing (PDF 32 KB)

Manufacturer submissions

Roche (PDF 28 KB)

Roche executive summary (PDF 229 KB)

Sanofi Aventis (PDF 97 KB)

Sanofi Aventis updated submission - new evidence (PDF 161 KB)

Sanofi Aventis executive summary (PDF 1.74 MB)

Expert written personal statements

Craven (PDF 31 KB)

Levine (PDF 17 KB)

Marks (PDF 23 KB)

Sharma (PDF 36 KB)

Final protocol (PDF 55 KB)

Final scope (PDF 26 KB)

Summary of consultee comments on the draft scope (PDF 44 KB)

Summary of consultee and commentator comments on provisional matrix (PDF 22 KB)

Archive: draft scope (PDF 27 KB)

Archive: provisional matrix of consultees and commentators (PDF 29 KB)